Trials, therapies, and evidence that changes care.
Europe PMC
Verdict: MajorTrastuzumab rezetecan (SHR-A1811) has demonstrated encouraging antitumor activity in a global phase 1 trial involving heavily pretreated patients with erythroblastic oncogene B (ERBB2)-low metastatic breast…
Trifluridine-tipiracil (FTD-TPI) plus bevacizumab is the standard treatment for refractory metastatic colorectal cancer.
Remibrutinib is a highly selective, potent, covalent, CNS-penetrant, oral BTK inhibitor.
In patients with IgA nephropathy, complement activation drives glomerular inflammation, which leads to hematuria, proteinuria, and nephron loss.
Sibeprenlimab, a humanized monoclonal antibody, selectively inhibits the cytokine A proliferation-inducing ligand (APRIL), a key driver of IgA nephropathy.
Retatrutide, an investigational triple agonist of glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors, may be useful for treating obstructive ....
It remains unclear if intraoperative hemodynamic therapy should be guided by cardiac index.